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Background: We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2
inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell lung cancer.
Methods: In this Phase I, open-label study (NCT01809210), treatment-naı¨ve patients received selumetinib (50, 75, 100mg BID PO)
plus standard doses of gemcitabine or pemetrexed plus cisplatin or carboplatin. Primary objectives were safety, tolerability, and
determination of recommended Phase II doses.
Results: Fifty-five patients received treatment: selumetinib 50 or 75mg plus gemcitabine/cisplatin (n¼ 10); selumetinib 50mg plus
gemcitabine/carboplatin (n¼ 9); selumetinib 50, 75 or 100mg plus pemetrexed/carboplatin (n¼ 21); selumetinib 75mg plus
pemetrexed/cisplatin (n¼ 15). Most frequent adverse events (AEs) were fatigue, nausea, diarrhoea and vomiting. Grade X3
selumetinib-related AEs were reported in 30 (55%) patients. Dose-limiting toxicities (all n¼ 1) were Grade 4 anaemia (selumetinib
75mg plus gemcitabine/cisplatin), Grade 4 thrombocytopenia/epistaxis and Grade 4 thrombocytopenia (selumetinib 50mg plus
gemcitabine/carboplatin), Grade 4 febrile neutropenia (selumetinib 100mg plus pemetrexed/carboplatin), and Grade 3 lethargy
(selumetinib 75mg plus pemetrexed/cisplatin). Partial responses were confirmed in 11 (20%) and unconfirmed in 9 (16%) patients.
Conclusions: Standard doses of pemetrexed/carboplatin or pemetrexed/cisplatin were tolerated with selumetinib 75mg BID. The
selumetinib plus gemcitabine-containing regimens were not tolerated.
Despite advances in the diagnosis, imaging, staging, and treatment
of non-small cell lung cancer (NSCLC), the estimated overall 5-
year survival rate for patients in Europe is only 11% (D’Addario
et al, 2010). A number of molecular abnormalities have been
shown to be characteristic of certain lung cancers and are used to
guide first-line treatment. Patients with tumours harbouring
activating epidermal growth factor receptor (EGFR) mutations
receive particular benefits from selective treatment with an EGFR
tyrosine kinase inhibitor, while patients with tumours that contain
the fusion oncogene EML4-ALK will benefit from targeting its
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tyrosine kinase activity using an ALK inhibitor, such as crizotinib
(Novello et al, 2016). However, there are no approved targeted
therapies for the majority of advanced NSCLC patients that have
no known or characterised molecular abnormalities and platinum-
based doublet chemotherapy is the first-line treatment for the vast
majority of patients.
Activation of the RAS/RAF/MEK/ERK (RAS-ERK) mitogen-
activated protein kinase pathway is implicated in cellular
proliferation and is central to driving cancer growth and
progression (Davies et al, 2002; Roberts and Stinchcombe, 2013).
Activation of this pathway can be driven by somatic mutations,
and KRAS mutations are found in up to 34% of NSCLC (Shepherd
et al, 2013). MEK1/2 are critical components of the RAS-ERK
pathway and therefore inhibition of MEK1/2 may be effective in
patients with NSCLC. Selumetinib (AZD6244, ARRY-142886) is
an oral, potent, and highly selective, allosteric MEK1/2 inhibitor
(Yeh et al, 2007), with a short half-life (Banerji et al, 2010; Denton
and Gustafson, 2011). In a prospective study, selumetinib in
combination with docetaxel, as second-line treatment for patients
with KRAS-mutant (KRASm) advanced NSCLC, improved pro-
gression-free survival (PFS) and objective response rate compared
with placebo combined with docetaxel (Ja¨nne et al, 2013). The
combination safety profile was consistent with those of the
individual components and adverse events (AEs) were manageable
with appropriate guidance and clinical practice (Shepherd et al,
2000; Hanna et al, 2004; Hainsworth et al, 2010; Ja¨nne et al, 2013).
Following these results, selumetinib was evaluated in combination
with docetaxel as second-line treatment in patients with KRASm
NSCLC in the Phase III SELECT-1 study (NCT01933932) (Ja¨nne
et al, 2016c).
Following the promising Phase II results of second-line
selumetinib, and in parallel to the Phase III SELECT-1 study, the
potential use of selumetinib in the first-line setting was investigated
in patients unselected for KRAS mutation status, to test the
hypothesis of MEK inhibition in the context of other non-KRASm
modes of pathway activation. To do this, the appropriate treatment
combinations of selumetinib plus chemotherapy were investigated
using platinum-doublet regimens that are standard of care for
treatment-naı¨ve patients, namely cisplatin or carboplatin, in
combination with either pemetrexed or gemcitabine (Reck et al,
2014). Here we report results from a dose-finding Phase I study
(NCT01809210), which assessed the safety, tolerability, and
preliminary efficacy of selumetinib in combination with first-line
chemotherapy regimens, in patients with NSCLC, unselected for
KRAS mutation status.
PATIENTS AND METHODS
Patients. Patients aged 18 years or older with histologically or
cytologically confirmed, locally advanced (stage IIIB) or metastatic
(stage IV) NSCLC, eligible for standard first-line platinum-doublet
treatment for NSCLC but unsuitable for radical treatment were
included in the study. Other eligibility criteria included World
Health Organization performance status (WHO-PS) of 0–1 and
radiologically measurable disease. Patients were not selected based
on KRAS mutation status, but local KRAS test results were
recorded if known.
Patients were excluded if they had received prior systemic anti-
cancer treatment for advanced NSCLC. Previous adjuvant
chemotherapy, prior surgery, or radiotherapy for curative intent
was permitted if they occurred 46 months prior to starting study
treatment. Other exclusion criteria included: treatment with potent
inhibitors or inducers of cytochrome P450 (CYP) 3A4/5, CYP2C19
and CYP1A2 within 2 weeks of the first dose of study treatment;
symptomatic brain metastases or spinal cord compression; history
of central serous retinopathy or retinal vein occlusion; uncon-
trolled glaucoma or intraocular pressure 421mmHg.
Study design and treatment. This was a Phase I/Ib, open-label,
multicentre study of selumetinib in combination with platinum-
doublet chemotherapy regimens, following a ‘rolling six’ design
with cohorts of at least three and up to six evaluable patients. The
study was designed to allow an investigation of the optimal
combination dose while ensuring the safety of patients with
intensive safety monitoring.
The primary study objective was to investigate the safety and
tolerability, and to determine the recommended Phase II dose
(RP2D) of selumetinib when administered in combination with
first-line chemotherapy regimens. Secondary objectives included
assessment of pharmacokinetics (PK) of selumetinib, its metabolite
N-desmethyl selumetinib, gemcitabine/pemetrexed and cisplatin/
carboplatin when administered in combination and evaluation of
tumour response to assess preliminary efficacy of the treatment
combinations using Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST v1.1).
Selumetinib was administered orally twice-daily (BID) in
continuous 21-day cycles. The starting dose of selumetinib was
chosen as 50mg being two-thirds of the combination dose used in
two Phase II studies (Kirkwood et al, 2012; Ja¨nne et al, 2013),
increasing in 25mg increments. Doses administered were selume-
tinib 50 or 75mg BID plus standard doses (for first-line treatment
of NSCLC) of gemcitabine (1250mgm 2) or pemetrexed
(500mgm 2) plus cisplatin (75mgm 2) or carboplatin
(AUC¼ 5). Only patients with non-squamous histology received
pemetrexed as per the approved indication. An additional dose-
finding cohort of selumetinib 100mg BID plus pemetrexed and
carboplatin was included. Primary prophylactic use of granulocyte
colony stimulating factors (GCSF) was not permitted, but GCSF
was permitted after Cycle 1.
Treatment was continued until a treatment or study
discontinuation criterion was met. Patients who discontinued
one, or both, chemotherapy agents were able to continue receiving
selumetinib monotherapy if there was evidence of continuing
clinical benefit as assessed by the investigator. The study was
designed to include an optional dose expansion study at the
recommended Phase II combination dose. The safety review
committee recommended that the pemetrexed/cisplatin cohort be
expanded to ascertain the safety and tolerability of this regimen, in
combination with the recommended Phase II dose of selumetinib
75mg BID.
The study followed the principles of the Declaration of Helsinki
and Good Clinical Practice guidelines of the International
Conference on Harmonisation. All patients provided written
informed consent prior to their participation in the study.
Approval was obtained from the local institutional review board
at each participating site and complied with local country
regulations.
Assessments. Safety was assessed in terms of AEs, laboratory data,
vital signs, electrocardiogram changes, physical examinations,
echocardiogram/multigated acquisition scan, and ophthalmologic
examinations. AEs were graded using the National Cancer Institute
CTCAE version 4.0. Dose-limiting toxicity (DLT) was assessed
during the first treatment cycle (a full definition of DLT is provided
in Supplementary Digital Content 1, Supplementary Methods).
Patients were followed up for 28±7 days following discontinuation
of selumetinib.
Plasma samples were collected for PK assessments at baseline
and on Cycle 1 Day 8 and Cycle 2 Day 1 for selumetinib and its
metabolite N-desmethyl selumetinib, gemcitabine and its metabo-
lite deoxy-1,1-difuorouridine (dFdu), pemetrexed, cisplatin (total
and/or unbound platinum) and carboplatin (total and/or unbound
platinum) (full details of the PK analysis are given in
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Supplementary Digital Content 1, Supplementary Methods)
(Severin et al, 2016).
Tumour response to treatment was assessed using RECIST v1.1
assessment of computed tomography or magnetic resonance
imaging scans at screening and then every 6 weeks for 6 months
and every 12 weeks thereafter until discontinuation of selumetinib.
Statistical analyses. Safety data were summarised for all patients
who received at least one dose of selumetinib. The PK analysis was
summarised for all patients with sufficient samples to provide an
adequate profile, with no important AEs or protocol deviations
that may have impacted PK. Plasma PK parameters were derived
using standard non-compartmental methods and actual elapsed
time from dosing. Efficacy data were summarised for all patients
who received at least one dose of selumetinib with a baseline
tumour assessment. Statistical analyses were performed by Phastar
(London, UK) under the direction of the Biostatistics Group,
AstraZeneca, (London, UK) using SAS software Version 9.1.3 or
later (SAS Institute, Inc. Cary, NC, USA).
RESULTS
Patient disposition. Between 4 April 2013 and 30 September
2015, 76 patients were enrolled; 21 failed to meet the eligibility
criteria and 55 received study treatment with selumetinib and first-
line chemotherapy regimens across seven dose escalation cohorts
(Figure 1). Ten patients were treated with gemcitabine and
cisplatin; nine with gemcitabine and carboplatin; 21 with
pemetrexed and carboplatin and 15 with pemetrexed and cisplatin.
Median treatment duration of selumetinib was 84 days (range,
4–266); median number of cycles of chemotherapy received are
displayed in Supplementary Table 1. All patients discontinued
selumetinib, due to the following reasons: AE (23 patients, 41.8%),
condition under investigation worsened (21 patients, 38.2%),
subject decision (11 patients, 20.0%). Nine patients died during
the study; two deaths were attributed to serious AEs of myocardial
infarction, two to disease progression and AEs (both colonic
perforation; one considered to be causally related to gemcitabine
and cisplatin) and five to disease progression alone. No deaths were
considered related to selumetinib.
Demographics and baseline disease characteristics. Overall,
demographics were as expected in patients with advanced NSCLC
and were generally balanced between treatment groups (Table 1),
with the exception of the male:female ratio of patients treated with
pemetrexed-cisplatin (2 : 1; n¼ 15). This was due to the sequential
enrolment process and the variable number of patients assigned to
each cohort. Most patients (66%) had a WHO-PS of 1 and the
majority had adenocarcinoma (67%). Fifty patients (91%) had
metastatic disease. KRAS mutation status was determined retro-
spectively using archival tumour samples in 28 patients (51%); six
(11%) had confirmed KRASm NSCLC. Of these six patients, five
had adenocarcinoma histology and for one patient the histology
could not be determined.
Safety. In total, five DLTs were reported (Supplementary Table 2).
The gemcitabine and cisplatin combination was tolerated at
selumetinib 50mg dose level. In the selumetinib 75mg plus
Gemcitabine (1250 mg m–2) on Day 1 and Day 8 q21
Carboplatin (AUC=5) on Day 1 q21
Cohort 2 (n = 9) selumetinib 50 mg BID
Pemetrexed (500 mg m–2) on Day 1 and Day 8 q21
Cisplatin (75 mg m–2) on Day 1 q21
Cohort 6 (n = 15)* selumetinib 75 mg BID
Gemcitabine (1250 mg m–2) on Day 1 and Day 8 q21
Cisplatin (75 mg m–2) on Day 1 q21
Cohort 1 (n = 3) selumetinib 50 mg BID
Cohort 3 (n = 7) selumetinib 75 mg BID
Pemetrexed (500 mg m–2) on Day 1 and Day 8 q21
Carboplatin (AUC=5) on Day 1 q21
Cohort 4 (n = 3) selumetinib 50 mg BID
Cohort 5 (n = 6) selumetinib 75 mg BID
Cohort 7 (n = 12) selumetinib 100 mg BID
Figure 1. Dose-escalation cohorts. *Includes patients from expansion cohort, after selumetinib 75mg BID dose was declared tolerated in
combination with pemetrexed and cisplatin.
Table 1. Patient demographics
Characteristic Total (n¼55)
Age (years)
Mean (range) 61.5 (39–76)
Gender, n (%)
Female 26 (47)
Male 29 (53)
Racial origin, n (%)
White 50 (91)
Black or African American 3 (6)
Other 2 (4)
Histology type, n (%)
Not determined 2 (4)
Squamous cell carcinoma 13 (24)
Adenocarcinoma 37 (67)
Adenocarcinoma: bronchiolo-alveolar 1 (2)
Other 2 (4)
KRAS mutation status, n (%)
Mutant 6 (11)
Mutation not detected 12 (22)
Unknown 37 (67)
Disease classification, n (%)
Locally advanced 5 (9)
Metastatic 50 (91)
WHO-PS, n (%)
0 19 (35)
1 36 (66)
Abbreviation: WHO-PS¼World Health Organization performance status.
BRITISH JOURNAL OF CANCER Selumetinib plus chemotherapy for NSCLC
940 www.bjcancer.com |DOI:10.1038/bjc.2017.271
gemcitabine and cisplatin group, one of four evaluable patients
experienced a DLT of Grade 4 anaemia; enrolment at selumetinib
75mg dose level was stopped by the study sponsor when two
serious AEs of large bowel perforation (at selumetinib dose levels
50 and 75mg), considered not related to selumetinib by the
investigators, were reported for this combination. The combination
of selumetinib 50mg plus gemcitabine and carboplatin was
declared non-tolerated, and two of seven evaluable patients
experienced DLTs: one Grade 4 thrombocytopenia, and one Grade
4 thrombocytopenia plus Grade 4 epistaxis. The pemetrexed and
carboplatin combination was tolerated at selumetinib 50 and 75mg
dose levels; no DLTs were reported. One of six evaluable patients in
the selumetinib 100mg plus pemetrexed and carboplatin group
experienced a DLT of Grade 4 febrile neutropenia. Although DLT
criteria were not reached for the selumetinib 100mg cohort, nine
(75%) patients required a dose modification and therefore this was
not considered suitable for evaluation in subsequent Phase II
studies. The combination of pemetrexed and cisplatin was not
explored at selumetinib 50mg dose level due to emerging data
from a Phase Ib trial study (NCT01783197) investigating
selumetinib (50 or 75mg BID) in combination with cisplatin and
pemetrexed or carboplatin and paclitaxel in patients with
previously untreated metastatic NSCLC. The trial demonstrated
that selumetinib 75mg BID was generally well tolerated in these
combinations (Nicholas et al, 2015). In the current study,
selumetinib in combination with pemetrexed and cisplatin was
found to be tolerated at 75mg from an expanded cohort of a total
of 12 evaluable patients: one patient in this group experienced a
DLT of Grade 3 lethargy. The RP2Ds were identified as
selumetinib 75mg BID plus standard doses of pemetrexed/
carboplatin and pemetrexed/cisplatin. No RP2Ds were defined
for treatment with gemcitabine; the carboplatin combination was
declared non-tolerated, and the combinations with cisplatin were
discontinued due to concerns about potential tolerability of this
regimen and the fatalities related to large bowel perforation.
The most commonly reported AEs overall were nausea (73%),
diarrhoea (55%), fatigue (55%), and vomiting (55%) (Table 2).
These were the most common AEs in each treatment arm except
for selumetinib plus gemcitabine/carboplatin, in which patients
reported fatigue, neutropenia, and thrombocytopenia most com-
monly (all 67%). In total, 44 (80%) patients experienced an AE of
Grade X3; the most common, regardless of causality, were
neutropenia (14, 26%), anaemia (12, 22%), and thrombocytopenia
(11, 20%). Thirty (55%) patients experienced an AE of Grade X3
causally related to selumetinib. AEs leading to a dose interruption
or discontinuation of selumetinib were observed in 29 (53%) and
23 (42%) patients, respectively. Serious AEs were observed in 33
(60%) patients. In 17 (31%) patients, serious AEs were considered
causally related to selumetinib by the investigator, of which 6
(11%) were thrombocytopenia.
AEs of particular interest due to their causal relationship to
selumetinib (as assessed by investigator) included facial oedema,
rash, retinal events, and decreases in left ventricular ejection
fraction (LVEF). Six patients experienced maculo-papular rash (all
Grade 1/2) with one patient discontinuing treatment due to this
AE; however, there were no cases of rash leading to a DLT. Twelve
patients experienced peripheral oedema with one instance leading
to treatment discontinuation; two patients experienced facial
oedema. Retinal vein occlusion, retinal pigment epithelial detach-
ment, and central serous retinopathy were each reported in one
patient receiving pemetrexed and cisplatin plus selumetinib 75mg
BID. No AEs of cardiac failure were reported. Decreased LVEF
causally related to selumetinib was reported in two patients (both
Grade 2). One patient who received gemcitabine and cisplatin plus
selumetinib 50mg BID experienced decreased LVEF 85 days after
the first dose of study treatment. LVEF was 64% at screening and
selumetinib was permanently discontinued due to the event, which
was assessed by the investigator as causally related to selumetinib,
when LVEF decreased to 51%. Another patient who received
pemetrexed and carboplatin plus selumetinib 50mg BID experi-
enced decreased LVEF with onset 170 days after the first dose of
study treatment. Echocardiography at screening showed an LVEF
of 62% with atrial dilation, which decreased to 33% and
selumetinib was interrupted. Selumetinib 50mg was continued
after 44 days when LVEF had increased to 41%. At the time of
treatment discontinuation, LVEF was 49% and the event was
recorded as ongoing (78 days after onset). Echocardiography
showed a mildly dilated left ventricular cavity with mildly impaired
systolic function and moderate dilation. Selumetinib was perma-
nently discontinued due to the event which was assessed by the
investigator as causally related to selumetinib.
Pharmacokinetics. PK analyses showed that the steady-state PK
of selumetinib and N-desmethyl selumetinib were generally similar
when administered with chemotherapy across the combination
regimens (Figure 2). Following oral administration of 50, 75, and
100mg BID, selumetinib was rapidly absorbed with a median time
to reach maximum plasma concentration (tmax) of 1.00–1.75 h
post-dose. No marked trend in time to reach maximum plasma
concentration at steady state (tss,max) was observed across
selumetinib dose or combination chemotherapies. With a low
number of evaluable PK parameters in some treatment groups,
selumetinib inter-patient variability of systemic exposure to
selumetinib was generally moderate to high, with geometric mean
Table 2. Most frequent AEs reported in at least 15% of
patients (full analysis set)
AE category, n (%) Any
grade
Grade
1
Grade
2
XGrade
3a
Patients with any AE 55 (100) 0 11 (20) 44 (80)
Nausea 40 (73) 17 (31) 15 (27) 8 (15)
Diarrhoea 30 (55) 26 (47) 3 (6) 1 (2)
Fatigue 30 (55) 13 (24) 15 (27) 2 (4)
Vomiting 30 (55) 20 (36) 9 (16) 1 (2)
Constipation 29 (53) 21 (38) 8 (15) 0
Rash 25 (46) 15 (27) 10 (18) 0
Decreased appetite 16 (29) 9 (16) 7 (13) 0
Neutropenia 16 (29) 0 2 (4) 14 (25)b
Periorbital oedema 16 (29) 12 (22) 4 (7) 0
Anaemia 15 (27) 0 3 (6) 12 (22)
Lethargy 14 (26) 7 (13) 5 (9) 2 (4)
Dyspnoea 13 (24) 4 (7) 6 (11) 3 (6)
Epistaxis 12 (22) 10 (18) 1 (2) 1 (2)
Oedema peripheral 12 (22) 7 (13) 5 (9) 0
Thrombocytopenia 12 (22)c 0 0 11 (20)d
Headache 11 (20) 8 (15) 3 (6) 0
Lower respiratory tract
infection
11 (20) 3 (6) 6 (11) 2 (4)
Oral candidiasis 11 (20) 10 (18) 1 (2) 0
Stomatitis 11 (20) 3 (6) 6 (11) 2 (4)
Abbreviations: AE¼ adverse event; CTCAE¼ common terminology criteria for adverse
events. Includes AEs with an onset date on or after the date of first dose and up to 35
(28±7) days following the date of last dose of selumetinib.
aPatients with multiple AEs of CTCAE Grade 3 or higher are counted once for each
preferred term.
bFour patients reported Grade 4 neutropenia, two each in the gemcitabineþ carboplatin
plus selumetinib 50mg and pemetrexedþ carboplatin plus selumetinib 100mg cohorts.
cOne AE of unknown grade.
dFive patients reported Grade 4 thrombocytopenia, three in the gemcitabineþ carboplatin
plus selumetinib 50mg cohort and two in the pemetrexedþ carboplatin plus selumetinib
100mg cohort.
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CV% for the area under the plasma concentration time curve in the
dosing interval (AUCt) and the maximum observed plasma
concentration at steady state (Css,max) ranging from 15%–57%
and 23%–76%, respectively, across treatment arms on Cycle 1 Day
8 and Cycle 2 Day 1. Visual assessment of PK parameters across all
treatment groups did not reveal any major differences in systemic
exposure, although there was a trend towards lower AUCt and
Css,max in patients receiving selumetinib 50mg plus gemcitabine
and cisplatin, with individual estimates ranging from 1590 to
2240 ng hml 1 and 276–686 ngml 1, respectively, across both
treatment cycles. However, this trend was not apparent in patients
receiving selumetinib 75mg plus gemcitabine and cisplatin. Mean
metabolite:parent AUCt ratios indicated that N-desmethyl selu-
metinib represented approximately 3–8% of selumetinib systemic
exposure, with no apparent trend in PK across treatment arms. The
PK of gemcitabine, dFdu, pemetrexed, cisplatin, and carboplatin
were generally similar across the doses of selumetinib administered
for the various combination chemotherapy regimens.
Efficacy. All 55 patients treated were evaluable for response, a
confirmed partial response was observed in 11 (20%) patients, and
an unconfirmed partial response in 9 (16%), resulting in an
estimated response rate of 36%. Figure 3 shows best percentage
change in tumour size. In addition, 21 (38%) patients had stable
disease at X6 weeks (Supplementary Table 3). Confirmed partial
responses were seen in: 3/10 (30%) patients receiving selumetinib
plus gemcitabine/cisplatin, 2/9 (22%) patients receiving selumeti-
nib plus gemcitabine/carboplatin (unconfirmed partial response in
3/9, 33%), 4/21 (19%) patients receiving selumetinib plus
pemetrexed/carboplatin (unconfirmed complete or partial
response in 4/21, 19%), and 2/15 (13%) patients in the selumetinib
plus pemetrexed/cisplatin treatment arm (unconfirmed complete
or partial response in 2/15, 13%). Of the six patients with KRASm
NSCLC detected using a local test, best objective response was 1
partial response; 3 stable disease; 2 progressive disease.
DISCUSSION
In the first-line setting, platinum-doublet chemotherapy represents
the standard of care for patients with advanced NSCLC without
EGFR activating mutation or ALK gene rearrangement, but
objective response rates are low (15–31%) and median survival is
generally up to approximately 10 months (Schiller et al, 2002;
Sandler et al, 2006; Scagliotti et al, 2008). Selumetinib, given in
combination with docetaxel, improved response rates and PFS in
the second-line setting (Ja¨nne et al, 2013); therefore, we investigated
whether selumetinib could be safely and effectively combined with
platinum-doublet chemotherapy in the first-line setting.
In the SELECT-3 study presented here, we identified recom-
mended Phase II doses of selumetinib 75mg BID when combined
with standard doses of pemetrexed and cisplatin or pemetrexed and
carboplatin, which were tolerated with AE profiles consistent with
the individual agents. The combinations with gemcitabine were not
tolerated and a recommended Phase II dose was not determined.
The overall safety profile of selumetinib in combination with
pemetrexed plus carboplatin or cisplatin was acceptable, and there
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Figure 2. Scatter plots of selumetinib (A–C) and N-desmethyl selumetinib (D–E) PK parameters (PK analysis set). AUCT = area under the plasma
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were no selumetinib-related deaths in any treatment arm. Many of
the AEs were those that would be anticipated from the
administration of platinum-doublet chemotherapy. The safety
profile presented here is consistent with a Phase Ib trial by the
National Cancer Institute of Canada (NCIC) investigating
selumetinib (50 or 75mg BID) combined with cisplatin and
pemetrexed or carboplatin and paclitaxel in patients with
previously untreated metastatic NSCLC (n¼ 22) (Nicholas et al,
2015). In the NCIC study, the most common selumetinib-related
toxicities were mild gastrointestinal and skin-related AEs. We also
observed generally mild skin and gastrointestinal toxicities,
although in the current study, six patients in the cisplatin-
containing treatment groups experienced XGrade 3 nausea (three
each in gemcitabine and cisplatin plus selumetinib 75mg, and
pemetrexed and cisplatin plus selumetinib 75mg groups). Owing
to the known emetogenic properties of cisplatin, we subsequently
agreed to a standardised anti-emetic regimen between participating
trial centres to include 3 days of steroids, a 5-HT3 receptor
antagonist, and aprepitant, and this would be recommended for
any subsequent studies of these combinations.
In our study the rate of Grade 3–4 neutropenia was lower than
that reported in the NCIC study (25% vs 44%) (Nicholas et al,
2015). In a previous Phase II study of selumetinib in combination
with docetaxel, rates of Grades 3–4 neutropenia were 67% in the
selumetinib plus docetaxel group, and 55% in the placebo plus
docetaxel group, without prophylactic GCSF treatment (Ja¨nne et al,
2013). In the current study, AEs were managed using safety
management guidelines according to standard clinical practice,
hence commonly occurring AEs were effectively managed using
specific treatment algorithms and GCSF was permitted after Cycle
1. Prophylactic GCSF was also used in the Phase III SELECT-1
study (Ja¨nne et al, 2016b). In the present study, two patients
experienced Grade 2 decreased LVEF considered causally related to
selumetinib. Reversible, asymptomatic reductions in LVEF have
been reported in a small number of patients in some studies of
selumetinib (Banerji et al, 2010). As such, mandatory safety
monitoring of LVEF with scheduled echocardiography assessments
and guidance to assist in the early diagnosis and management of
decreased LVEF have been incorporated into trial protocols,
including that of the SELECT-3 trial.
The recommended Phase II dose was not determined for the
gemcitabine-containing regimens, due to fatalities of unknown
relationship to the combinations and therefore a tolerable regimen
was not identified for patients with squamous NSCLC in this study.
The carboplatin combination was not tolerated, while the combina-
tions with cisplatin were discontinued due to fatalities related to
colonic perforation: two patients (one receiving selumetinib 50mg
plus gemcitabine/cisplatin; one receiving selumetinib 75mg plus
gemcitabine/cisplatin) experienced large intestine perforation leading
to death 50 days and 25 days after the first dose of selumetinib,
respectively. These AEs were not deemed by the investigator to be
related to selumetinib in the present study, although this effect has
been reported with other MEK inhibitors (Minor et al, 2015). By
contrast, a manageable toxicity profile was reported at a dose of
75mg BID selumetinib plus gemcitabine 1000mgm 2 and cisplatin
25mgm 2 in a Phase Ib trial in patients with advanced or metastatic
biliary tract cancer (Bridgewater et al, 2016). However, this may be
due to the lower doses of both gemcitabine and cisplatin, and the
fractioned regimen of cisplatin, or the variation in comorbidities of
the patients enrolled.
Combination therapy did not appear to show any marked effect
on the PK profile of selumetinib or its metabolite N-desmethyl
selumetinib. It was noted that there was a trend for lower systemic
exposure to selumetinib in the selumetinib 50mg plus gemcitabine
and cisplatin treatment group, but due to the limited data in this
study and high variability of selumetinib PK, no conclusions can be
made regarding the significance of this finding. While the study
was not designed to assess whether selumetinib affects the exposure
of the chemotherapies investigated, the available data did not find
any marked differences in the PK of gemcitabine, pemetrexed,
cisplatin and carboplatin, across the doses of selumetinib
administered for the various combination chemotherapy regimens.
Preliminary anti-tumour activity was observed across all
treatment arms. Confirmed partial responses were detected in
20% of patients and 38% of patients had stable disease at X6
weeks. Data for each arm were consistent with previous reports of
chemotherapy alone (Karampeazis et al, 2016; Langer et al, 2016;
Park et al, 2017a,b). Six patients (40%) in the pemetrexed plus
cisplatin group opted to continue with the standard maintenance
therapy of pemetrexed. Maintenance therapy with selumetinib was
not robustly explored in this study.
This trial was initiated before immunomodulatory therapies
were approved for the treatment of patients with NSCLC in the
second-line setting. Based on encouraging results from studies of
these agents (Besse et al, 2015; Gettinger et al, 2016; Rizvi et al,
2016), several Phase III trials are currently evaluating immu-
notherapies in the first-line setting as monotherapy, in combina-
tion with different immunotherapies, or with platinum-based
chemotherapy. The Keynote-024 study has shown higher response
rate, PFS and overall survival for pembrolizumab when compared
with standard platinum-based doublet chemotherapy as first-line
treatment for patients with advanced NSCLC with high levels
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Figure 3. Best percentage change in tumour size. Abbreviations: carb¼ carboplatin; cis¼ cisplatin; gem¼gemcitabine; pem¼pemetrexed;
sel¼ selumetinib. n¼47. Eight patients were excluded due to incomplete post-baseline assessments of tumour response. Best change in target lesion size
is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction. *Patients with detected KRAS mutation.
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(450%) of PD-L1 expression (Reck et al, 2016). Despite the
rapidly changing treatment landscape, it is not anticipated that all
patients will benefit from immunotherapy, particularly those
patients whose tumours are PD-L1 negative or low (Qin et al,
2016). Therefore, it is expected that platinum-doublet chemother-
apy will continue to be used in the first-line setting for certain
patient populations, especially if PD-L1 testing becomes more
widely used, and will likely be used in relapse for patients following
first-line immunotherapy. However, it should be noted that the
efficacy and safety profile of subsequent treatments may be altered
following first-line immune checkpoint inhibition. Selumetinib is
being investigated in combination with the PD-L1 inhibitor
durvalumab for patients with advanced solid tumours, including
lung cancer, in the Phase I SELECT-4 trial (NCT02586987).
A limitation of the present study is that patients were not
prospectively evaluated for KRAS mutation status, therefore sub-
populations of patients deriving clinical benefit could not be
identified. Limited KRAS mutation information was obtained from
local test results using different methodologies with various limits
of detection and coverage. The rate of KRASm in adenocarcinoma
and squamous NSCLC is approximately 34% and 6%, respectively
(Shepherd et al, 2013), with a higher incidence in Western
compared with Asian populations (Dogan et al, 2012; Dearden
et al, 2013). Although many agents have been developed to target
this element of the RAS-ERK pathway, clinical efficacy data have
been mixed (Kempf et al, 2016). Direct inhibition of RAS
activation using salirasib failed to show clinical efficacy in patients
with stage IIIB/IV lung adenocarcinoma KRAS mutations (Riely
et al, 2011). In patients with NSCLC who were treated with the
multitarget tyrosine sorafenib in the third or fourth-line setting,
post-hoc analyses found that KRAS mutation status was not
predictive of efficacy (Mok et al, 2012).
The Phase I NCIC study has been expanded into a Phase II trial
investigating selumetinib in patients receiving pemetrexed and
platinum-based chemotherapy in advanced or metastatic non-
squamous NSCLC without a detected KRAS mutation or with an
unknown KRAS mutation status (NCT02337530). Selumetinib has
also been explored in combination with docetaxel as a second-line
treatment in patients with KRASm advanced NSCLC in the SELECT-
1 trial. However, no difference in PFS (primary endpoint), overall
survival, or objective response rate was observed (Ja¨nne et al, 2016c).
Owing to the large number of co-mutations in patients with KRASm
NSCLC, the specific patient subgroup that may derive benefit from
selumetinib remains to be determined. Consequently, no further
clinical trials are currently planned with selumetinib in this setting.
Exploratory analyses from the SELECT-1 trial demonstrated that
there was no evidence that treatment effect on PFS differed by
specific KRAS mutation status (determined by next-generation
sequencing) (Ja¨nne et al, 2016a). Similarly, PD-L1 status did not
significantly impact PFS, overall survival, or objective response rate in
either the selumetinib plus docetaxel or docetaxel alone treatment
groups (Ja¨nne et al, 2016a). However, selumetinib monotherapy has
demonstrated clinical benefit in patients with neurofibromatosis type
1 (Dombi et al, 2016), which may warrant investigation of the utility
of selumetinib for neurofibromatosis type 1 mutant NSCLC tumours
(Redig et al, 2016).
In conclusion, our study demonstrates that selumetinib can be
combined with standard doses of pemetrexed plus carboplatin or
cisplatin in the first-line setting with an AE profile consistent with
the individual agents.
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